LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

Начало・Списък с акции・Pulse Biosciences Inc

Pulse Biosciences Inc

Затворен

СекторЗдравеопазване

21.31 2.75

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.51

Максимум

21.69

Ключови измерители
By Trading Economics
Приходи	2M -17M
Продажби	178K 264K
EPS	-0.257
Марж на печалбата	-6,603.409
Служители	116
EBITDA	2M -17M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+43.33% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-179M 958M
Предишно отваряне	18.56
Предишно затваряне	21.31

Настроения в новините

By Acuity

76%

24%

317 / 350 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.59 / 17.17 Подкрепа & съпротива

Pulse Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.03.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23.03.2026 г., 22:55 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23.03.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23.03.2026 г., 23:59 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

23.03.2026 г., 23:59 ч. UTC

Пазарно говорене

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23.03.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23.03.2026 г., 22:42 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

23.03.2026 г., 22:42 ч. UTC

Пазарно говорене

Значими събития в новините

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23.03.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23.03.2026 г., 22:23 ч. UTC

Пазарно говорене

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23.03.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23.03.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23.03.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23.03.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23.03.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23.03.2026 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23.03.2026 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23.03.2026 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23.03.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23.03.2026 г., 22:08 ч. UTC

Пазарно говорене

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23.03.2026 г., 21:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.03.2026 г., 21:42 ч. UTC

Пазарно говорене

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23.03.2026 г., 21:10 ч. UTC

Значими събития в новините

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Значими събития в новините

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pulse Biosciences Inc Прогноза

Ценова цел

By TipRanks

43.33% нагоре

12-месечна прогноза

Среден 30 USD 43.33%

Висок 30 USD

Нисък 30 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Pulse Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Pulse Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.59 / 17.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Настроение

By Acuity

317 / 350 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.